Paul Matteis
Stock Analyst at Stifel
(3.07)
# 1,243
Out of 5,124 analysts
128
Total ratings
46.51%
Success rate
0.76%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Buy | $50 → $40 | $22.31 | +79.29% | 3 | Dec 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $183 → $188 | $137.35 | +36.88% | 11 | Dec 11, 2025 | |
| LBRX LB Pharmaceuticals | Maintains: Buy | $27 → $35 | $19.89 | +75.97% | 2 | Dec 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $36 → $39 | $18.12 | +115.23% | 5 | Dec 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $495 → $508 | $406.40 | +25.00% | 16 | Dec 11, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $24 → $25 | $26.94 | -7.20% | 6 | Dec 11, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $28 | $17.01 | +64.61% | 1 | Nov 21, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Hold | $2 → $3 | $1.82 | +64.84% | 3 | Nov 17, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Hold | $73 → $61 | $60.07 | +1.55% | 11 | Nov 6, 2025 | |
| BIIB Biogen | Upgrades: Buy | $144 → $202 | $182.61 | +10.62% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $455 → $445 | $468.38 | -4.99% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $43 → $67 | $81.49 | -17.78% | 6 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $6.84 | +75.44% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $99.42 | -5.45% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $37.22 | -14.02% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $14.12 | +126.63% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $7.05 | +56.03% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.69 | +136.69% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $15.08 | -33.69% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $18.30 | +227.87% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $28.78 | +25.09% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $27.66 | +26.54% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $9.49 | +205.58% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $9.51 | +110.30% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.72 | +1,562.97% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $360 → $50 | $6.95 | +619.42% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $15.75 | +103.17% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.96 | +1,277.55% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $21.50 | -34.88% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $15.15 | +322.44% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $221.38 | +53.58% | 1 | Dec 21, 2016 |
uniQure
Dec 11, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $22.31
Upside: +79.29%
Neurocrine Biosciences
Dec 11, 2025
Maintains: Buy
Price Target: $183 → $188
Current: $137.35
Upside: +36.88%
LB Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $27 → $35
Current: $19.89
Upside: +75.97%
Dyne Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $18.12
Upside: +115.23%
Alnylam Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $495 → $508
Current: $406.40
Upside: +25.00%
ACADIA Pharmaceuticals
Dec 11, 2025
Maintains: Hold
Price Target: $24 → $25
Current: $26.94
Upside: -7.20%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $17.01
Upside: +64.61%
Neumora Therapeutics
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $1.82
Upside: +64.84%
BioMarin Pharmaceutical
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $60.07
Upside: +1.55%
Biogen
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $182.61
Upside: +10.62%
Nov 4, 2025
Maintains: Hold
Price Target: $455 → $445
Current: $468.38
Upside: -4.99%
Oct 6, 2025
Maintains: Hold
Price Target: $43 → $67
Current: $81.49
Upside: -17.78%
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $6.84
Upside: +75.44%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $99.42
Upside: -5.45%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $37.22
Upside: -14.02%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $14.12
Upside: +126.63%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $7.05
Upside: +56.03%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.69
Upside: +136.69%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $15.08
Upside: -33.69%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $18.30
Upside: +227.87%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $28.78
Upside: +25.09%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $27.66
Upside: +26.54%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $9.49
Upside: +205.58%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $9.51
Upside: +110.30%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $0.72
Upside: +1,562.97%
Jun 23, 2022
Downgrades: Hold
Price Target: $360 → $50
Current: $6.95
Upside: +619.42%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $15.75
Upside: +103.17%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.96
Upside: +1,277.55%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $21.50
Upside: -34.88%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $15.15
Upside: +322.44%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $221.38
Upside: +53.58%